Abstract Long non-coding RNAs (lncRNAs) are important for transcription and for epigenetic or posttranscriptional regulation of gene expression and may contribute to carcinogenesis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), an lncRNA involved in the regulation of the cell cycle, cell proliferation, and cell migration, is known to be deregulated in multiple cancers. Here, we analyzed the expression of MALAT1 on 195 cases of benign and malignant thyroid neoplasms by using tissue microarrays for RNA in situ hybridization (ISH) and real-time PCR. MALAT1 is highly expressed in normal thyroid (NT) tissues and thyroid tumors, with increased expression during progression from NT to papillary thyroid carcinomas (PTCs) but is downregulated in poorly differentiated thyroid cancers (PDCs) and anaplastic thyroid carcinomas (ATCs) compared to NT. Induction of epithelial to mesenchymal transition (EMT) by transforming growth factor (TGF)-beta in a PTC cell line (TPC1) led to increased MALAT1 expression, supporting a role for MALAT1 in EMT in thyroid tumors. This is the first ISH study of MALAT1 expression in thyroid tissues. It also provides the first piece of evidence suggesting MALAT1 downregulation in certain thyroid malignancies. Our findings support the notion that ATCs may be molecularly distinct from low-grade thyroid malignancies and suggest that MALAT1 may function both as an oncogene and as a tumor suppressor in different types of thyroid tumors.
Introduction
Thyroid cancer is the most common malignancy of endocrine organs with enormous heterogeneity in terms of morphological features and prognosis [1] . Although the majority of thyroid carcinomas tend to be biologically indolent and have an excellent prognosis, some are associated with more aggressive clinical behaviors [2] . Most thyroid cancers are derived from thyroid follicular epithelial cells, which are further divided into well-differentiated papillary thyroid carcinoma (PTC) and follicular carcinomas (FCs), as well as poorly differentiated carcinoma (PDC) and anaplastic thyroid carcinoma (ATC) based on histological features [1] . Despite extensive research on morphological subclassification and immunohistochemistry characters, it remains difficult to accurately predict disease progression and high-grade transformation in various thyroid malignancies.
The transcription of RNAs without obvious coding potential led to the discovery of non-coding RNAs (ncRNAs), which have distinct expression pattern in different tissues/organs/developmental stages and are increasingly recognized as a key regulatory element of proliferation, differentiation, and apoptosis [3] . Long non-coding RNAs (lncRNAs) are generally defined as ncRNAs that are longer than 200 nucleotides. Compared to other shorter ncRNAs (e.g., microRNAs (miRNAs), tRNAs) that are better studied, lncRNAs are more numerous and diverse. Dysregulation of lncRNAs has been associated with various malignancies of multiple organs, including the breast, liver, prostate, bladder, intestine, and brain [3] . In the thyroid, several lncRNAs have been proposed as susceptibility markers of cancers especially papillary thyroid carcinoma, such as papillary thyroid cancer susceptibility candidate 1 (PTCSC1) [4] , PTCSC2 [5] , and PTCSC3 [6, 7] . In addition, a few lncRNAs may be related to the pathogenesis of thyroid cancers, including BANCR [8] and PVT1 [9] .
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), an lncRNA that participates in the regulation of cell cycle and migration, is known to be deregulated in malignancies in multiple organs, including the lung, uterus, cervix, breast, colon, pancreas, stomach, kidney, bladder, and bone [10] . In this study, RNA in situ hybridization (ISH) of MALAT1 was performed on tissue microarrays (TMAs) constructed from 195 cases of normal thyroid tissues and chronic lymphocytic thyroiditis, as well as benign and malignant thyroid neoplasms. The results were further validated by realtime PCR. We found that MALAT1 is highly expressed in thyroid tissues, with upward trend from normal thyroid (NT) to benign neoplasm then to the well-differentiated thyroid cancers (PTCs and FCs). Interestingly, it is downregulated in PDCs and ATCs. In addition, induction of epithelial mesenchymal transition (EMT) by transforming growth factor (TGF)-beta led to increased MALAT1 expression in a PTC cell line. These results may shed new light on the categorization of thyroid neoplasms and the understanding of their pathogenesis.
Materials and Methods

Tissue Microarrays
TMAs were constructed as described previously [11, 12] from 195 case samples of formalin-fixed, paraffin-embedded tissues, including NT (n = 10), Hashimoto thyroiditis (HT; n = 12), nodular goiters (NG; n = 10), follicular adenoma (FA; n = 32), FC (n = 28), conventional papillary thyroid carcinoma (cPTC; n = 28), follicular variant of papillary thyroid carcinoma (FV; n = 29), PDC (n = 21), and ATC (n = 35). The TMA consisted of triplicate 0.6-mm cores made using a manual TMA (Beecher Instruments, Sun Prairie, WI). The NT consisted of tissues from the opposite (histologically normal) thyroid lobe in patients with follicular or papillary carcinomas.
The study was approved by the Institutional Review Board at the University of Wisconsin-Madison.
In Situ Hybridization
TMAs were probed for MALAT1 expression using the RNAscope 2.0 HD-Brown Manual Assay (Advanced Cell Diagnostics, Newark, CA, USA) as per manufacturer's recommendations with the following modifications: antigen retrieval for 15 min, protease digestion for 30 min, probe incubation overnight at 40°C, and amplification steps 1-4 only (steps 5 and 6 were omitted due to high expression). The probes used are hs-MALAT1 (400811), hs-ACTB (Actin, positive control, 310141), and dapB (negative control, 310043) (Advanced Cell Diagnostics). MALAT1 expression levels were visualized with DAB and quantitated using an automated image acquisition and analysis system.
Automated Image Acquisition and Analysis
The stained TMA slides were visualized and analyzed with the Vectra slide scanner as previous described [13] . Briefly, after image acquisition, any core with tissue folding or loss of tissue was excluded for analysis. InForm 1.4.0 software was used to segment tissue compartments (epithelium vs. non-epithelium) and subcellular compartments (nucleus vs. cytoplasm). MALAT1 expression level from each sample was quantitated as optical density (OD) per unit area (pixel) and normalized to the total pixel counts obtained from each cell. Only nuclear signal was used for analysis. Mean MALAT1 expression level of each case was used for further analysis.
Real-Time PCR
Total RNA was extracted from samples with TRIzol reagent (ThermoFisher Scientific, Waltham, MA) according to the manufacturer's instructions, and RNA quality and concentrations were assessed with a NanoDrop 1000 spectrophotometer (ThermoFisher Scientific, Waltham, MA). One microgram of total RNA was reverse transcribed using the All-in-One miRNA RT-qPCR Detection Kit (GeneCopoeia Rockville, MD). RT-qPCR was performed on a CFX96 PCR detection system (Bio-Rad Laboratories, Hercules, CA) using Bullseye EvaGreen qPCR master mix (MIDSCI, St. Louis, MO), normalized to 18S rRNA; relative fold change was determined by the ΔΔCT method. The PCR primers used are Malat1; forward 5′-GACGGAGGTTGAGATGAAGC-3′ and reverse 5′-ATTCGGGGCTCTGTAGTCCT-3′, and 18S; forward 5′-GTAACCCGTTGAACCCCATT-3′ and reverse 5′-CCAT CCAATCGGTAGTAGCG-3′.
Tissue Culture and EMT Induction with TGF-β
The papillary thyroid carcinoma cell line TPC1 was cultured and treated with TGF-β to induce EMT as previously described [14, 15] . Briefly, TPC1 cells were treated with serum-free media with and without TGF-β (2ng/ml) [14, 15] .
Statistics
Student's t test was used to analyze MALAT1 expression data collected from RNA ISH and real-time PCR. Two-tailed pvalues of <0.05 were considered to be statistically significant. Data are expressed as means ± standard error of the mean (SEM).
Results
ISH of MALAT1
MALAT1 ISH was performed on three TMAs containing 10 NT, 12 HT, 10 NGs, 32 FAs, 28 FCs, 28 cPTCs, 29 FVs, 21 PDCs, and 35 ATCs, and automated image acquisition and analysis were performed as described in the BMaterials and Methods^section. MALAT1 shows a dot-like nuclear staining pattern, which is typical for lncRNAs (Fig. 1 ). Moderate to strong nuclear expression of MALAT1 was seen in NT as well as benign neoplasms and well-differentiated thyroid cancers, including NGs, FAs, FCs, and cPTCs. However, the signal for MALAT1 in PDCs and ATCs is low (Figs. 1 and 2) . The positive control actin probe showed strong cytoplasmic labeling and weaker nuclear stain labeling. The negative controls did not show any labeling in the thyroid tissues. Interestingly, cytoplasmic staining was also present but was several folds lower than the nuclear staining in all types of thyroid tumors examined.
As shown in Fig. 2 , a trend of increasing MALAT1 expression was observed from NT and HT to benign neoplasms to well- differentiated cancers, with the highest expression level observed in cPTCs, despite lack of statistically significant difference among cPTCs, FCs, NGs, and FAs. MALAT1 expression is significantly higher in cPTCs compared to NT (p = 0.014). Interestingly, MALAT1 expression level in FV is similar to NT and is significantly lower than cPTCs (p = 0.016). On the other hand, MALAT1 expression in PDCs and ATCs is significantly lower than NT (p < 0.01), with ATCs expressing significantly lower MALAT1 than PDCs (p < 0.01).
Real-Time PCR of MALAT1 in Thyroid Cancers
To confirm the ISH findings, MALAT1 expression level was studied using real-time PCR in FFPE tissues from a subset of cPTCs, FCs, PDCs, and ATCs used on the TMAs. As seen in Fig. 3 , MALAT1 expression level was significantly higher in the cPTCs compared to the other groups (p < 0.05).
TGF-β Treatment
After 14 and 21 days of TGF-β treatment, MALAT1 RNA levels were significantly increased compared to the control groups indicating induction of MALAT1 expression during EMT (Fig. 4) . Our previous studies had also shown an increase in the EMT markers SLUG and OCT4 in the TPC1 cell line with EMT [14, 15] .
Discussion
The role of lncRNAs in pathogenesis is increasingly recognized. MALAT1, a well-known lncRNA and possible oncogene [16] , is upregulated in malignancies of multiple organs [10] . RNA ISH enables direct visualization of lncRNAs, and strong MALAT1 hybridization signals were previously reported in breast malignancies [17] . In this study, we examined the expression level of MALAT1 in normal thyroid tissue as well as benign and malignant neoplasms using ISH and real-time PCR validation. We found strong nuclear staining of MALAT1 in both normal thyroid tissues and thyroid neoplasms, with upregulation during progression from NT to benign neoplasm then to the well-differentiated thyroid cancers (PTCs and FCs). It is worth noting that HTs, which is an inflammatory condition rather than neoplasm, showed essentially the same MALAT1 expression level as in NT. This further supports that MALAT1 dysregulation is potentially specific for tumorigenesis.
Different from cPTCs, FVs, especially the encapsulated FVs, usually have an indolent disease course. This feature was recently further characterized which led to the adoption of the new terminology Bnon-invasive follicular thyroid neoplasm with papillary-like nuclear features^(NIFTP) for a subgroup of benign neoplasms previously categorized into PCTs [18] . TMAs used in this study were constructed prior to the introduction of NIFTP terminology, and the possible NIFTPs were not excluded from the FV group. Thus, despite the low expression of MALAT1 in some FVs that could support the notion that FVs might be pathogenetically different from cPTCs and generally behave in benign fashion, we are unable to draw definitive conclusions without separating NIFTPs from FVs in our current study.
MALAT1 expression in PDCs and ATCs are significantly lower than NT, with the expression in ATCs showing the lowest levels. This is the first report of MALAT1 being It is worth noting that other relatively well-studied ncRNAs in the thyroid, such as miR146b, share similar trends of being upregulated in PTCs and FCs while downregulated in ATCs [12] . Interestingly, while being more known for its oncogenic features, miR-146b is also proposed to be a tumor suppressor [19] . It is possible that similar to miR-146b, depending on the cancer subtype, MALAT1 functions both as an oncogene and as a tumor suppressor.
Various lncRNAs have been shown to have a role in EMT [3] . The present study showed that TGF-β treatment, which we have used previously to induce EMT in thyroid cell lines [14, 15] , led to increased MALAT1 expression in the PTC cell line. Our previous studies showed that during EMT in thyroid cell lines, there was increased cell proliferation and cell migration as well as increased in tumor growth in immunodeficient mice [14] . In addition, EMT was also associated with increased in the numbers of cancer stem cells [14, 15] , suggesting that MALAT1 may have a role in cancer stem cell proliferation in thyroid tumors.
Although extensive molecular studies have been performed on PTCs including studies of microRNAs expressed by PTCs [20] , only limited molecular studies have been done in PDTCPDC and ATCs [21] [22] [23] . Thus, the role of lncRNAs in the regulation of ATCs has not been analyzed. The recent study of Huang et al. [24] on thyroid carcinoma cell lines suggested that FC cell line FTC133 expressed higher levels of MALAT1 compared to the SW1736 ATC cell line. Since our studies showed that PTC tumors had higher levels of MALAT1 compared to FCs and ATCs, the molecular mechanisms regulating differences in MALAT1 expression in these various thyroid tumor types must await further studies.
In summary, we characterized the expression pattern of MALAT1 in thyroid tissues and showed that it is dysregulated in thyroid carcinomas in this study. This study also showed that MALAT1 expression is upregulated in PTC cells during TGF-β-induced EMT. Our results suggest that lncRNAs such as MALAT1 may be important in thyroid cancer pathogenesis and may be useful for the classification of thyroid cancers. Further studies are needed to illustrate the function of MALAT1 and other lncRNAs in thyroid cancer, which may convey diagnostic and prognostic values. 
